journal article·2023-09Open access

Small Extracellular Vesicle‐Derived vWF Induces a Positive Feedback Loop between Tumor and Endothelial Cells to Promote Angiogenesis and Metastasis in Hepatocellular Carcinoma

Samuel Wan Ki Wong, Sze Keong Tey, Xiaowen Mao, Hiu Ling Fung, Zhi‐Jie Xiao, Danny Ka Ho Wong, Lung‐Yi Mak, Man‐Fung Yuen, Irene Oi‐Lin Ng, Jing Ping Yun, Yi Gao, Judy Wai Ping Yam

Advanced Science· Volume 10· Issue 26

Abstract

Abstract Hepatocellular carcinoma (HCC) is a hypervascular malignancy by which its growth and dissemination are largely driven by the modulation of tumor‐derived small extracellular vesicles (sEVs). Proteomic profiling of circulating sEVs of control individuals and HCC patients identifies von Willibrand factor (vWF) to be upregulated progressively along HCC stages. Elevated sEV–vWF levels are found in a larger cohort of HCC–sEV samples and metastatic HCC cell lines compared to their respective normal counterparts. Circulating sEVs of late‐stage HCC patients markedly augment angiogenesis, tumor–endothelial adhesion, pulmonary vascular leakiness, and metastasis, which are significantly compromised by anti‐vWF antibody. The role of vWF is further corroborated by the enhanced promoting effect of sEVs collected from vWF‐overexpressing cells. sEV–vWF modulates endothelial cells through an elevated level of vascular endothelial growth factor A (VEGF‐A) and fibroblast growth factor 2 (FGF2). Mechanistically, secreted FGF2 elicits a positive feedback response in HCC via the FGFR4/ERK1 signaling pathway. The co‐administration of anti‐vWF antibody or FGFR inhibitor significantly improves the treatment outcome of sorafenib in a patient‐derived xenograft mouse model. This study reveals mutual stimulation between HCC and endothelial cells by tumor‐derived sEVs and endothelial angiogenic factors, facilitating angiogenesis and metastasis. It also provides insights into a new therapeutic strategy involving blocking tumor–endothelial intercellular communication.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Extracellular vesicles in disease · MicroRNA in disease regulation · Ferroptosis and cancer prognosis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pathology School of Clinical Medicine Li Ka Shing Faculty of Medicine The University of Hong Kong Hong Kong

Department of Surgery School of Clinical Medicine Li Ka Shing Faculty of Medicine The University of Hong Kong Hong Kong

State Key Laboratory of Liver Research, The University of Hong Kong Hong Kong

Research Centre The Seventh Affiliated Hospital Sun Yat‐sen University 518107 Shenzhen P. R. China

Department of Medicine School of Clinical Medicine Li Ka Shing Faculty of Medicine The University of Hong Kong Hong Kong

Department of Pathology Sun Yat‐sen University Cancer Center Guangzhou Guangdong 510060 P. R. China

Department of Hepatobiliary Surgery II ZhuJiang Hospital Southern Medical University Guangzhou Guangdong 510280 P. R. China

References (55)

Show source-provided references
1. Rawla P. · Contemp. Oncol. · 2018 · 22 · 141
2. 10.1038/s41575-019-0186-y10.1038/s41575-019-0186-y ↗
3. 10.1016/j.jhep.2004.09.00610.1016/j.jhep.2004.09.006 ↗
4. 10.1097/PPO.000000000000013810.1097/PPO.0000000000000138 ↗
5. 10.3390/ijms2212623410.3390/ijms22126234 ↗
6. 10.3390/cells907160110.3390/cells9071601 ↗
7. 10.1002/jev2.1209610.1002/jev2.12096 ↗
8. 10.1158/1541-7786.MCR-20-082710.1158/1541-7786.MCR-20-0827 ↗
9. 10.1080/20013078.2017.135947910.1080/20013078.2017.1359479 ↗
10. 10.3390/cancers1412295310.3390/cancers14122953 ↗
11. 10.1016/j.omtn.2018.02.01410.1016/j.omtn.2018.02.014 ↗
12. 10.1016/j.jhep.2021.12.00510.1016/j.jhep.2021.12.005 ↗
13. 10.1002/(SICI)1097-0215(20000115)85:2<281::AID-IJC21>3.0.CO;2-310.1002/(SICI)1097-0215(20000115)85:2<281::AID-IJC21>3.0.CO;2-3 ↗
14. 10.1002/jcla.2221910.1002/jcla.22219 ↗
15. 10.1002/cam4.74710.1002/cam4.747 ↗
16. 10.1016/j.tranon.2021.10103310.1016/j.tranon.2021.101033 ↗
17. 10.1186/s12885-015-1083-610.1186/s12885-015-1083-6 ↗
18. 10.1016/j.cell.2020.07.00910.1016/j.cell.2020.07.009 ↗
19. 10.1021/acsomega.0c0540810.1021/acsomega.0c05408 ↗
20. 10.1111/jth.1355110.1111/jth.13551 ↗
21. 10.1016/j.lfs.2009.01.00510.1016/j.lfs.2009.01.005 ↗
22. 10.1091/mbc.e04-05-037410.1091/mbc.e04-05-0374 ↗
23. 10.1038/sj.onc.120526010.1038/sj.onc.1205260 ↗
24. 10.1002/wdev.17610.1002/wdev.176 ↗
25. 10.1016/j.thromres.2007.03.01110.1016/j.thromres.2007.03.011 ↗
26. 10.1007/s12185-015-1913-y10.1007/s12185-015-1913-y ↗
27. 10.3748/wjg.v11.i14.216610.3748/wjg.v11.i14.2166 ↗
28. 10.1007/s12032-023-01950-w10.1007/s12032-023-01950-w ↗
29. 10.3389/fonc.2021.63960010.3389/fonc.2021.639600 ↗
30. 10.21037/jtd-20-345310.21037/jtd-20-3453 ↗
31. 10.1016/j.thromres.2018.11.02610.1016/j.thromres.2018.11.026 ↗
32. 10.1038/s41598-021-02254-710.1038/s41598-021-02254-7 ↗
33. 10.1007/s11010-021-04254-710.1007/s11010-021-04254-7 ↗
34. 10.1038/s41598-022-13272-410.1038/s41598-022-13272-4 ↗
35. 10.1182/blood-2010-01-26450710.1182/blood-2010-01-264507 ↗
36. 10.1182/blood.201900051010.1182/blood.2019000510 ↗
37. 10.1160/TH16-12-095710.1160/TH16-12-0957 ↗
38. 10.1016/j.taap.2022.11592710.1016/j.taap.2022.115927 ↗
39. 10.1016/j.jacbts.2021.12.00510.1016/j.jacbts.2021.12.005 ↗
40. 10.1016/S0753-3322(00)00006-810.1016/S0753-3322(00)00006-8 ↗
41. 10.1002/ijc.2984710.1002/ijc.29847 ↗
42. Brock T. A. · Am. J. Pathol. · 1991 · 138 · 213
43. 10.18632/oncotarget.1427310.18632/oncotarget.14273 ↗
44. 10.1038/s41419-021-04410-310.1038/s41419-021-04410-3 ↗
45. 10.1158/0008-5472.CAN-04-144310.1158/0008-5472.CAN-04-1443 ↗
46. 10.1158/1535-7163.MCT-08-001310.1158/1535-7163.MCT-08-0013 ↗
47. 10.1002/hep.3192110.1002/hep.31921 ↗
48. 10.1186/s13046-016-0478-910.1186/s13046-016-0478-9 ↗
49. Chen X. · Oxid. Med. Cell Longevity · 2022 · 202210.1155/2022/2543220 ↗
50. 10.1002/hep.51031012610.1002/hep.510310126 ↗
51. 10.1073/pnas.120606210910.1073/pnas.1206062109 ↗
52. 10.1016/j.cell.2006.05.03010.1016/j.cell.2006.05.030 ↗
53. 10.1101/sqb.2005.70.05910.1101/sqb.2005.70.059 ↗
54. 10.1002/advs.20200215710.1002/advs.202002157 ↗
55. 10.1002/jev2.1203110.1002/jev2.12031 ↗